Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT06708949 | A Randomized Phase 2 Trial of Nivolumab, Relatlimab Plus Ipilimumab vs. Nivolumab Plus Ipilimumab in First-line Advanced Renal Cell Carcinoma (RCC) | PHASE2 | RECRUITING | 15 | — | — | Mar 20, 2025 | Dec 15, 2028 | May 14, 2026 | 6 | United States |
Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0
| Arm | Type | Description |
|---|---|---|
| Treatment with Nivolumab + Ipilimumab | EXPERIMENTAL | Participants will randonmized to study and treatment will be administered on an outpatient basis. |
| Treatment with Nivolumab + Relatlimab + Ipilimumab | EXPERIMENTAL | Participants will randonmized to study and treatment will be administered on an outpatient basis. |
| Name | Type | Description |
|---|---|---|
| Drugs Nivolumab | DRUG | Given by IV Infusion |
| Ipilimumab | DRUG | Given by IV Infusion |
| BMS-986213 (Relatlimab-Nivolumab FDC) | DRUG | Given by IV Infusion |
Inclusion Criteria: 1. Willing and able to provide a signed and dated written informed consent. 2. ≥ 18 years of age 3. Confirmed diagnosis of RCC with a clear cell component 4. Stage IV metastatic renal cell carcinoma per American Joint Committee on Cancer 5. No prior systemic therapy for RCC. Pri...